June 1, 2021

A Population-Based Analysis of the Longevity of SARS-CoV-2 Antibody Seropositivity in the United States

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): antibodies, immunity

• An observational study of 39,086 US individuals with PCR-confirmed COVID-19 followed up to 10 months from March 2020 to January 2021 found that prevalence of anti-SARS-CoV-2 IgG spike (S) and nucleocapsid (N) antibodies reached approximately 90% 21 days after infection, then declined to 88% for S antibodies and 68% for N antibodies after 10 months. Those aged <65 years showed a more sustained prevalence of antibodies over time.

Alfego et al. (May 2021). A Population-Based Analysis of the Longevity of SARS-CoV-2 Antibody Seropositivity in the United States. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.100902